Another Japanese firm has partnered for an obesity compound that is under review by the FDA. This time, Takeda Pharmaceutical Co. Ltd. has agreed to pay at least $1.05 billion to market Orexigen Therapeutics Inc.'s Contrave in North America. (BioWorld Today) Read More
